CD4 and metabolic syndrome: In this subsample, the prevalence of MetS according to the EGIR criteria was as follows: overall: 12.4%; men versus women: 6.7% versus 13.9%, p = 0.018; shorter versus longer duration of diagnosed HIV infection: 9.5% versus 15.2%, p = 0.022; CD4 count < 392 cells/mm3 versus ≥392 cells/mm3: 7.9% versus 17.2, p = 0.007; and ART regimens: 10.1% (1st line), 19.4% (2nd line), and 14.4% (other regimens) (p = 0.051) (Table S1).